vs
Side-by-side financial comparison of BayCom Corp (BCML) and ENANTA PHARMACEUTICALS INC (ENTA). Click either name above to swap in a different company.
BayCom Corp is the larger business by last-quarter revenue ($25.9M vs $18.6M, roughly 1.4× ENANTA PHARMACEUTICALS INC). BayCom Corp runs the higher net margin — 26.5% vs -64.1%, a 90.6% gap on every dollar of revenue. On growth, ENANTA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.8% vs 9.4%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $-11.8M). Over the past eight quarters, ENANTA PHARMACEUTICALS INC's revenue compounded faster (4.5% CAGR vs 2.9%).
BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
BCML vs ENTA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $18.6M |
| Net Profit | $6.9M | $-11.9M |
| Gross Margin | — | — |
| Operating Margin | 36.6% | -60.5% |
| Net Margin | 26.5% | -64.1% |
| Revenue YoY | 9.4% | 9.8% |
| Net Profit YoY | 12.1% | 46.4% |
| EPS (diluted) | $0.63 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.9M | $18.6M | ||
| Q3 25 | $25.7M | $15.1M | ||
| Q2 25 | $24.7M | $18.3M | ||
| Q1 25 | $24.3M | $14.9M | ||
| Q4 24 | $23.7M | $17.0M | ||
| Q3 24 | $25.6M | $14.6M | ||
| Q2 24 | $23.8M | $18.0M | ||
| Q1 24 | $24.5M | $17.1M |
| Q4 25 | $6.9M | $-11.9M | ||
| Q3 25 | $5.0M | $-18.7M | ||
| Q2 25 | $6.4M | $-18.3M | ||
| Q1 25 | $5.7M | $-22.6M | ||
| Q4 24 | $6.1M | $-22.3M | ||
| Q3 24 | $6.0M | $-28.8M | ||
| Q2 24 | $5.6M | $-22.7M | ||
| Q1 24 | $5.9M | $-31.2M |
| Q4 25 | 36.6% | -60.5% | ||
| Q3 25 | 26.3% | -121.6% | ||
| Q2 25 | 35.3% | -103.2% | ||
| Q1 25 | 31.6% | -164.3% | ||
| Q4 24 | 34.2% | -138.8% | ||
| Q3 24 | 32.4% | -204.4% | ||
| Q2 24 | 31.9% | -134.6% | ||
| Q1 24 | 33.3% | -192.1% |
| Q4 25 | 26.5% | -64.1% | ||
| Q3 25 | 19.5% | -123.6% | ||
| Q2 25 | 25.8% | -99.7% | ||
| Q1 25 | 23.4% | -151.7% | ||
| Q4 24 | 25.9% | -131.4% | ||
| Q3 24 | 23.5% | -197.3% | ||
| Q2 24 | 23.6% | -126.1% | ||
| Q1 24 | 24.0% | -182.7% |
| Q4 25 | $0.63 | $-0.42 | ||
| Q3 25 | $0.46 | $-0.88 | ||
| Q2 25 | $0.58 | $-0.85 | ||
| Q1 25 | $0.51 | $-1.06 | ||
| Q4 24 | $0.55 | $-1.05 | ||
| Q3 24 | $0.54 | $-1.36 | ||
| Q2 24 | $0.50 | $-1.07 | ||
| Q1 24 | $0.51 | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $37.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.6M | $126.6M |
| Total Assets | $2.6B | $329.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $37.4M | ||
| Q3 25 | — | $32.3M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $60.2M | ||
| Q4 24 | — | $84.3M | ||
| Q3 24 | — | $37.2M | ||
| Q2 24 | — | $35.8M | ||
| Q1 24 | — | $63.5M |
| Q4 25 | $338.6M | $126.6M | ||
| Q3 25 | $334.3M | $64.7M | ||
| Q2 25 | $330.6M | $79.3M | ||
| Q1 25 | $329.3M | $93.5M | ||
| Q4 24 | $324.4M | $111.8M | ||
| Q3 24 | $321.7M | $128.8M | ||
| Q2 24 | $315.3M | $148.9M | ||
| Q1 24 | $314.2M | $166.1M |
| Q4 25 | $2.6B | $329.5M | ||
| Q3 25 | $2.6B | $280.7M | ||
| Q2 25 | $2.6B | $301.0M | ||
| Q1 25 | $2.6B | $323.0M | ||
| Q4 24 | $2.7B | $348.6M | ||
| Q3 24 | $2.6B | $376.7M | ||
| Q2 24 | $2.6B | $398.8M | ||
| Q1 24 | $2.6B | $413.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.8M | $-11.7M |
| Free Cash FlowOCF − Capex | $30.1M | $-11.8M |
| FCF MarginFCF / Revenue | 116.2% | -63.6% |
| Capex IntensityCapex / Revenue | 6.7% | 0.8% |
| Cash ConversionOCF / Net Profit | 4.64× | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.1M | $-18.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | $-11.7M | ||
| Q3 25 | $7.3M | $-6.5M | ||
| Q2 25 | $6.4M | $17.5M | ||
| Q1 25 | $9.3M | $-13.5M | ||
| Q4 24 | $30.4M | $-16.8M | ||
| Q3 24 | $9.6M | $-10.4M | ||
| Q2 24 | $7.7M | $-14.8M | ||
| Q1 24 | $5.1M | $-28.6M |
| Q4 25 | $30.1M | $-11.8M | ||
| Q3 25 | $6.2M | $-7.9M | ||
| Q2 25 | $5.6M | $17.4M | ||
| Q1 25 | $9.1M | $-16.0M | ||
| Q4 24 | $28.7M | $-25.5M | ||
| Q3 24 | $9.4M | $-19.4M | ||
| Q2 24 | $7.4M | $-21.3M | ||
| Q1 24 | $3.9M | $-30.3M |
| Q4 25 | 116.2% | -63.6% | ||
| Q3 25 | 24.3% | -52.5% | ||
| Q2 25 | 22.8% | 94.7% | ||
| Q1 25 | 37.6% | -107.4% | ||
| Q4 24 | 121.1% | -150.6% | ||
| Q3 24 | 36.6% | -132.5% | ||
| Q2 24 | 31.2% | -118.6% | ||
| Q1 24 | 16.1% | -177.5% |
| Q4 25 | 6.7% | 0.8% | ||
| Q3 25 | 4.3% | 9.6% | ||
| Q2 25 | 3.0% | 0.8% | ||
| Q1 25 | 0.6% | 17.0% | ||
| Q4 24 | 7.2% | 51.6% | ||
| Q3 24 | 1.0% | 61.3% | ||
| Q2 24 | 1.0% | 36.4% | ||
| Q1 24 | 4.7% | 9.8% |
| Q4 25 | 4.64× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 0.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
